If you are interested in knowing what FDA thinks about important regulatory issues, including specific product reviews, it is time to renew ...

The Food & Drug Administration's public health alert on Plavix is, as we point out in "The Pink Sheet" DAILY , a nice boos...

When Big Pharma execs start pointing to unusual performance metrics when talking about big product launches, investors get very nervous. Wha...

So will personalized medicine be the death of primary care? Maybe not. Maybe just the opposite. In this edition of the IN VIVO Blog Podcast ...

Sanjay Kaul doesn’t get discouraged easily. The very public debacle over Kaul’s potential intellectual conflict of interest with Lilly/Daiic...

We here at the IN VIVO Blog do love our advisory committee meetings. The anticipation. The preparation. The smell of the reams of briefing...

Eli Lilly and Daiichi Sankyo used the morning of New Years Eve (‘tis the season for hiding news) to announce that the delayed anti-clotting ...

The gap just got wider. No, we’re not talking about the income inequality gap, or the gender gap, or the generation gap. We’re talking about...

The election is near and Washington is rife with chatter about who will go where in the next administration. But FDA made a Washington appoi...

We knew the story on the prasugrel delay was big, but maybe not quite this big. If you hadn’t already heard, it appears a decision by FDA ...

It looks like FDA’s decision on Eli Lilly’s anti-clotting drug prasugrel won’t come before March 2009 at the earliest. Members of FDA’s C...

Another NDA, another missed deadline. This time around, it’s a product upon which Eli Lilly has hung much of its future, the anti-clotting d...

Eli Lilly’s prasugrel team may have some free time on its hands in August and September if FDA’s advisory committee calendar is any indicato...

Attention will now turn to a tentative August 19-20 FDA Cardiovascular and Renal Drugs Advisory Committee meeting date as the next major pra...

[Update: Well, it looks like Lilly will have to wait on the champagne, at least for now. FDA extended the review of prasugrel by three month...

Lilly shareholders woke up this morning to find their company suddenly worth $1.4 billion more than it was at the close of trading yesterday...

Steve Nissen's latest star turn , advising doctors everywhere to stop using Vytorin until there is better evidence it improves health ou...

The speculation about the prospects for Lilly’s clot prevention drug prasugrel continues. The latest turn has been a rebound for Lilly, prom...

We were a bit taken aback by Lilly CEO Sidney Taurel’s editorial in the Wall Street Journal earlier this week recounting the damage done by ...